Glaucoma needs different tools at different stages. Nova Eye supports the full patient journey, from interventional, angle-based MIGS options like canaloplasty to drainage devices.
Our flagship illuminated microcatheter with easy-to-use ergonomic handpiece is built to support angle-based MIGS procedures, including canaloplasty, with a workflow that is practical to perform, teach and repeat.
The original iTrack™ microcatheter, with a proven track record in canaloplasty dating back to 2008 and used in more than 150,000 procedures globally.
A glaucoma drainage device for severe and complex glaucoma cases. Built around a slim, contoured 4mm polypropylene plate that sits close to the sclera.
We build glaucoma devices with the same care and precision surgeons bring to the OR. Our work at Nova Eye Medical is shaped by real-world clinical practice and refined with surgeon input—for intuitive, flexible glaucoma solutions that enhance patient lives.
Nova Eye cares about doing what’s best for physicians and working with physicians to do better for patients, for the industry and the future of glaucoma.
I. Paul Singh, MD (USA)
You know in real time that you are actually breaking adhesions and opening up that canal
Rachel Gartell-Simpson, MD (USA)
I now consider early intervention with canaloplasty for almost any glaucoma patient– it is the obvious choice for outflow restoration.
Shamil Patel, MD, MBA (USA)
With canaloplasty you’re revamping the entire system, rather than just a fraction of it.
Analisa Arosemena, MD (USA)
Canaloplasty tries to keep things physiologic. It leaves nothing behind in terms of any tissue destruction or implantation and tries to deal with the pathology.
Ike K. Ahmed, MD, FRCSC (Canada)
I had to know that whatever intervention I was going to offer would truly have a benefit for my patients. Each of these concerns—whether it would interrupt my surgical flow and whether it worked—are what led me to learn more about canaloplasty, and more specifically about the iTrack™ Advance from Nova Eye Medical
William F. Wiley, MD (USA)
Educational offerings featuring Nova Eye Medical products and glaucoma procedures
Straight from the Nova Eye news desk.
The iTrack™ Advance has a CE Mark (Conformité Européenne) 2862 and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma.
INDICATIONS (International): The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open angle glaucoma.
CONTRAINDICATIONS (International): The iTrack™ Advance is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: Neovascular glaucoma; Angle-closure glaucoma; Previous surgery with resultant scarring of Schlemm’s canal.
ADVERSE EVENTS (International): Possible adverse events with the use of the iTrack™ Advance include, but are not limited to: hyphema, elevated IOP, Descemet’s membrane detachment, shallow or flat anterior chamber, hypotony, trabecular meshwork rupture, choroidal effusion, Peripheral Anterior Synechiae (PAS) and iris prolapse.
PRECAUTIONS (International): The iTrack™ Advance should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.
For full safety information, visit: https://itrack-advance.com
© 2026. Nova Eye, Inc. E&OE. Patents pending and/orgranted.
iTrack™ Advance, iTrack™, ViscoInjector™ and iLumin™ are trademarks of Nova Eye,Inc.
